Biotech "Tweets of the Week"
Valentine's Day Double Feature
(February 8-19, 2016)
Featuring:
$ABBV $AERI $AVXS $BCRX $BGNE $BLUE $CPRX $CTIC $EDIT $FLXN $HEB $ICPT $INCY $PTI $RGLS $SRPT
$XBI $IBB $LABU
#BIOCEO16, Celltrion, Biosimilars, Advisory Committee, Refuse-to-file (RTF), Drug Prices
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
The IPO Hangover $EDIT $BGNE $PTI $AVXS
$EDIT fell off a cliff with #BIOCEO16 CRISPR panel this afternoon. Now off 20% from IPO.
— PropThink (@PropThinker) February 9, 2016
Same-day IPO $BGNE up 15% from $24 pricing.
Although not official as there is currently no S-1A, the $PTI #IPO will likely adjust terms to 6.25m at $8.00. Remains a $50m cash raise.
— IPO Boutique (@IPOBoutique) February 10, 2016
$AVXS AveXis prices #IPO. 4.75M shares at $20/sharehttps://t.co/kygbPWi784
— Bio Stocks™ (@BioStocks) February 10, 2016
So you want to IPO a biotech now? how cute... Proteostasis Therapeutics $PTI priced at $8 (intial range $12-14) pic.twitter.com/PjJO16X090
— Jean Fonteneau (@JFinDallas) February 11, 2016
$PTI planned $12~14 range, priced at $8, immediately down 20%+ out of gate despite existing stockholders took more than half of the #IPO...
— Andy Biotech (@AndyBiotech) February 11, 2016
Breaking bad: all IPOs YTD break issue. #IPO $AVXS $PTI $BGNE $EDIT pic.twitter.com/Bgbl2ztg4Q
— Renaissance Capital (@IPOtweet) February 11, 2016
Clinical trial trouble for CTI, Biocryst, and Incyte $CTIC $BCRX $INCY
$CTIC -- FDA places pacritinib studies on partial clinical hold due to "excessive mortality." Gr. 5 events deja vu. Explains everything.
— Adam Feuerstein (@adamfeuerstein) February 8, 2016
$BCRX OPuS-2 trial of #avoralstat in hereditary angioedema attacks failshttps://t.co/phDIDfH28R#rarediseases #pharma #biotech
— Donna Young (@ScripDonnaDC) February 8, 2016
$BCRX $2.05. Down 66%
— Shane Blackmon (@shaneblackmon) February 8, 2016
. @mxd Everything touched by Jim Bianco turns to shit eventually. It’s one of the immutable laws of biotech. $CTIC
— Adam Feuerstein (@adamfeuerstein) February 8, 2016
$BCRX Avoralstat 300 mg TID arm did worse than placebo on multiple endpoints... #FAIL pic.twitter.com/cFTVSsv1On
— Andy Biotech (@AndyBiotech) February 8, 2016
$CTIC and $BCRX get taken back to the wood shed for another spanking. How do these #biotech co.s retain investors?
— John Carroll (@JohnCFierce) February 8, 2016
$CTIC - interim OS results from PERSIST-2 showed > # of deaths in pacritinib patients: Brain bleeds, heart attacks, heart failure.
— Adam Feuerstein (@adamfeuerstein) February 10, 2016
Wowza!!
Oh, you know that partial hold it took us 4 days to disclose? It's actually a full hold. NDA withdrawn. As you were! $CTIC
— Jacob Plieth (@JacobPlieth) February 10, 2016
$CTIC downgraded to Sell at WallachBeth, PT $0
— Bio Stocks™ (@BioStocks) February 10, 2016
$INCY ending JANUS studies of #ruxolitinib in advanced/metastatic #PancreaticCancer https://t.co/ApqyVGWtIY #pharma #biotech
— Donna Young (@ScripDonnaDC) February 11, 2016
$INCY - Expanding Jakafi into solid tumors was important to the growth thesis, now gone.
— Adam Feuerstein (@adamfeuerstein) February 11, 2016
$INCY stock is paying the price mostly because their overzealous expansion w/ruxolitinib trials implied a raise in expectations by mgmt.
— Ozgur Ogut (@Ogut_Ozgur) February 11, 2016
$CTIC is up 24% today. You know biotech euphoria is heating up when that one starts floating again on any recovery.
— Sheff (@SheffStation) February 16, 2016
bianco sells 100k at $0.42...atta boy! $CTIC
— zach (@zbiotech) February 19, 2016
Luminaries talk drug prices at #BIOCEO16
Sen. Schumer: Americans are torn. They see drugs save lives. Other hand, prices go thru roof for certain drugs #BIOCEO16
— Luke Timmerman (@ldtimmerman) February 8, 2016
Isaly: speed of info way faster now than yrs ago. I used to get ASCO abstracts FedExed. Now, push of button, whole world knows #BIOCEO16
— Luke Timmerman (@ldtimmerman) February 8, 2016
.@popsalks FDA driven by data. Not anecdotes, or amalgams of anecdotes #BIOCEO16
— Luke Timmerman (@ldtimmerman) February 9, 2016
Scangos sounded a little jumpy/defensive on pricing. Yes, he said, we raised Avonex prices. Q is what did we do w/ the $? #BIOCEO16
— Luke Timmerman (@ldtimmerman) February 9, 2016
indeed, scangos...you have plowed those hundreds of millions into a risky pIII alz asset....ie, 'let it ride' $BIIB
— zach (@zbiotech) February 9, 2016
I don't believe Scangos argument that without lots of price hikes on avonex Biogen wouldnt have developed other drugs for MS #bioceo16
— Chris Morrison (@CT_Morrison) February 9, 2016
When $BIIB CEO Scangos threatens to stop developing drugs bc of lower prices, he reinforces view profits more impt than patients. #BIOCEO16
— Adam Feuerstein (@adamfeuerstein) February 9, 2016
@adamfeuerstein @ltimmerman Or they won't buyback $5B of stocks, imagine that, terrible... pic.twitter.com/izL6kP7Ayv
— Jean Fonteneau (@JFinDallas) February 9, 2016
Scott Gottlieb: if industry loses the pricing debate in Washington, the govt could start setting price caps #BIOCEO16
— Jessica Merrill (@Jessicaemerrill) February 9, 2016
.@roncohenshair When you get a winner, like HCV, you see investment came from many people over decades. Wasn't just the winner #BIOCEO16
— Luke Timmerman (@ldtimmerman) February 9, 2016
.@roncohenshair we've heard outrage before on pricing. Questcor made headlines. But now the issue is sticking. #BIOCEO16
— Luke Timmerman (@ldtimmerman) February 9, 2016
Celltrion's favorable FDA Advisory Committee for biosimilar Humira
#FDA Christl: Reminds adcomm Celltrion #CTP13 is not seeking interchangeability, only biosimilarity$JNJ #Remicade #biosimilars #biosimilar
— Donna Young (@ScripDonnaDC) February 9, 2016
Chrisl - There is no pivotal Ph III clinical trial in a #bioisimilar program; it's a totality of the evidence approach
— Sue Sutter (@PinkSheetSutter) February 9, 2016
This adcomm is going Billy Dee Williams smooth for Celltrion. So far.
— Ramsey Baghdadi (@Ramsey_Baghdadi) February 9, 2016
.@matthewherper I think Amgen is FOR the biosimilars it makes and AGAINST the biosimilars others make. Zing! #BIOCEO16
— Luke Timmerman (@ldtimmerman) February 9, 2016
#ctp13adcom; FDA moves on to extrapolation, arguably the most important topic this afternoon
— Biosimilarz (@biosimilarz) February 9, 2016
#ctp13adcom; would be stunned if CT-P13 doesn't get a full label after the extrapolation presentation... pic.twitter.com/AGLFAq1WGp
— Biosimilarz (@biosimilarz) February 9, 2016
There is ongoing IBD study, what would Co. do if data fails? It’s not a regulatory study only done for stakeholders and educate prescribers.
— SAC Tracker (@FDAadcomm) February 9, 2016
FDA's Kozlowski - If you always need the comfort of clinical efficacy data, you defeat the core purpose of the BPCIA pathway
— Sue Sutter (@PinkSheetSutter) February 9, 2016
#AAC votes 21-3 that totality of evidence supports approval of Celltrion's CT-P13 as #biosimilar 4 all available #Remicade indications
— Sue Sutter (@PinkSheetSutter) February 9, 2016
Bluebird Bio is a poster child for sentiment shifts $BLUE
@sharkbiotech More fun than wasting my money on Biotwitter cult stocks $BLUE $SRPT $RLYP. I'd rather invest in cash reserves than in lies.
— Tony Friedman (@zzlangerhans) February 11, 2016
Oppenheimer abandons coverage of $BLUE
— KSS, MD, PhD (@KSSMDPhD) February 12, 2016
$PGNX..up 18%, $CUR up 18%, $GLYC up 25%, $PETX up 14%, $BLUE up 13%, $RMTI up 19%, & $KMPH up 13%, $LABU up 13% ..biotech moves of the day!
— Sheff (@SheffStation) February 16, 2016
First patient in $BLUE’s cancer immunotherapy (multiple myeloma) program has been dosed!
— Brad Loncar (@bradloncar) February 17, 2016
Roth:" $BLUE TP=$62: Drove a CAR-T to the Clinic=Wise Choice; $CELG chose to opt in to co-develop bb2121 by paying $10MM milestone payment."
— Tom Silver (@TomSilver39) February 19, 2016
Catalyst slammed with FDA "Refuse to File" letter $CPRX
How embarrassing. Catalyst $CPRX gets a refuse-to-file letter on Firdapse NDA -- https://t.co/ZahGD39eW3
— John Carroll (@JohnCFierce) February 17, 2016
$CPRX Geez what's the last time that we saw a damning "Refusal To File "letter? $PFE tafamidis or $PTCT ataluren?
— Andy Biotech (@AndyBiotech) February 17, 2016
$CPRX bit of karma
— zach (@zbiotech) February 17, 2016
$CPRX -50% in PreM on RTF
— 23aloha (@23aloha) February 17, 2016
I spoke with $CPRX longs who said Jacobus just didn't have the expertise to get the NDA right on first pass/timely. Whoops
— PropThink (@PropThinker) February 17, 2016
Data from Flexion, Regulus, and Aerie met with questions $FLXN $RGLS $AERI
$FLXN 10.90
— Tom Wrigley (@WrigleyTom) February 16, 2016
Flexion Therapeutics Reports Primary Endpoint Met in Pivotal Phase 3 Trial of Zilretta™ in Knee O... https://t.co/ZFGRqEkv6D
After reading $FLXN PR half-dozen times, appears FX006 failed against active control (but did beat placebo.) File under: Who cares?
— Adam Feuerstein (@adamfeuerstein) February 16, 2016
$RGLS announces Ph2 RG-101 interim analysis showing 97% response at 8 weeks for treatment of #HCV. Read: https://t.co/gHiAY0F2UK
— Regulus Therapeutics (@RegulusRx) February 17, 2016
$RGLS Caveat is how SVR8 will translate to viable SVR24 with 4 wk TX. Probably still some way to go
— j l (@bio_clouseau) February 17, 2016
@RNAiAnalyst no virologic breakthroughs or relapses observed. #HCVsandwich $rgls
— Dirk Haussecker (@RNAiAnalyst) February 17, 2016
$FLXN So how does a product with two failed trials compete against a cheap generic and entrenched larger companies in the OA space?
— Vikram Khanna (@VikramKhanna_) February 17, 2016
@adamfeuerstein Why is $RGLS reporting RG-101 data in terms of HCV assay’s level of *quantification* rather than level of detection?
— Roy Friedman (@DewDiligence) February 17, 2016
$FLXN will seek pre-NDA meeting over phIII data where Zilretta failed to beat generic triamcinolone. Still plans H2 2016 filing
— Jacob Plieth (@JacobPlieth) February 17, 2016
You know what’s on investors’ minds when efficacy is the fourth bullet point in $AERI’s PR after 3 discussing safety.
— Brad Loncar (@bradloncar) February 17, 2016
$AERI Rhopressa safety further worsened at 12mo vs 3mo,but of course they call it "positive"https://t.co/cGQINFBNVb pic.twitter.com/apmaqYyt1u
— Andy Biotech (@AndyBiotech) February 17, 2016
$AERI — Our glaucoma eye drop is safe except for all the horrible things it does to your eyes. Don’t worry, you won’t be able to see anyway.
— Adam Feuerstein (@adamfeuerstein) February 17, 2016
$AERI - 'nothing to see here'...literally
— zach (@zbiotech) February 18, 2016
As seen on the stream
Opioid induced constipation and now Xifaxan IBS/diarrhea commercial. No wonder the general public thinks the Pharma industry is full of shit
— Brian Gallagher, Jr. (@bmgallagherjr) February 8, 2016
$SRPT eteplirsen pdufa extended to May 26; new date for ad com not yet given https://t.co/DXuwWU9ZW0
— Meg Tirrell (@megtirrell) February 8, 2016
Constants in life:
— Adam Feuerstein (@adamfeuerstein) February 9, 2016
The sun rises in the east. $HEB exploits public health scare to pump its stock price.
BioPharmCatalyst updates: $SRPT PDUFA date extension. $BCRX Phase 2 fail. $CTIC partial hold+ $RNN $OMED $CYTX $BOTA https://t.co/vNZh2EGzVF
— BioPharmCatalyst (@crusadernz) February 9, 2016
Market not even open yet $IBB already down 3.5%, $REGN miss, biotech stocks being crushed on flat ER has been the standard so when miss...
— Jean Fonteneau (@JFinDallas) February 9, 2016
$OTIC in $12s. DCF Otiprio = it alone worth ~$20/sh. Problem is gradual launch expected and we're in clinical data lull. No defense
— chillipickle (@chillipickle7) February 9, 2016
Interesting panel on market outlook at #BIOCEO16. Market ugly but fundamentals still strong. Vulnerable are those who need to raise $ soon.
— Julia Owens (@juliacowens) February 9, 2016
$MSTX what an "EPIC" stock offering.... Down 35% AH's. Management showing confidence about Phase 3 EPIC trial with this raise.
— Shane Blackmon (@shaneblackmon) February 9, 2016
People who did not want to be long overnight still outnumber people who do not want to be short. Not encouraging.
— David Miller (@AlpineBV_Miller) February 10, 2016
Tough deadline. Makes me think Walgreens does not want Theranos to succeed in meeting it. @matthewherper @cdweaver
— Bob More (@Bobmorevc) February 11, 2016
Hilarious $AMPE press release. About that conference call comment about not needing to raise money… https://t.co/2SoTTi0hFD
— Brad Loncar (@bradloncar) February 11, 2016
@JFinDallas @CGrantWSJ If so, we'll see a filing soon - $edit wasn't helped earlier in wk when US intel chief incl gene therapy as a WMD.
— 23aloha (@23aloha) February 11, 2016
Interesting that UCLA have developed a new approach for DMD using gene edited stem cell therapy: https://t.co/OZvyFwoiGG #CRISPR
— Sally Church (@MaverickNY) February 12, 2016
Lots of new adcomms scheduled, except for $SRPT. Is it possible FDA won’t reschedule the eteplirsen panel?
— Adam Feuerstein (@adamfeuerstein) February 12, 2016
ALERT: Shares of Intercept resume & soar 20% after circuit breaker; Reuters reports company is exploring sale. $ICPT
— CNBC Now (@CNBCnow) February 12, 2016
$ICPT Rachel McMinn sets company sale bid floor at $872 per share. "I'll settle for my old BofA price target, nothing less."
— Adam Feuerstein (@adamfeuerstein) February 12, 2016
$ICPT sale seen “exceedingly low” prior to FDA panel scheduled for April 7, Wells Fargo says
— Sasha Damouni Ellis (@SashaDamouni) February 12, 2016
$XBI $IBB closed pennies from HoD -- for the most part, bios have round tripped or moved down in 2016, so this was a standout day.
— 23aloha (@23aloha) February 12, 2016
$MRK gets a CRL for Zetia/Vytorin for cardio --https://t.co/qy6Go6Aywo
— John Carroll (@JohnCFierce) February 15, 2016
Quantifying The Carnage: Biotech IPO Markets In Turmoil - 74% of 2013-2016 IPOs are under their offer price. https://t.co/o65kdNhJ2Y
— Bruce Booth (@LifeSciVC) February 15, 2016
Yesterday I spoke with a trusted source who is long $GILD. On the M&A question he was clear: "I want them to wait."
— Charley Grant (@CGrantWSJ) February 15, 2016
$CPXX Celator Pharmaceuticals VYXEOS Phase 3 in AML Reaches Required Number of Events for OS Analysis
— BioBreakout (@BioBreakout) February 16, 2016
@rajramaswamy $PGNX. Yup out as of today with last 1/3. Still not convinced bio bear is dead. Ample opportunity to re-enter
— BioHunter (@TheBio_Hunter) February 16, 2016
@bradloncar yup, also, clinical trials page was updated before they put PR out.
— vlad33301 (@vlad33301) February 16, 2016
@sharkbiotech @zDonShimoda Owning it is like riding a horse or a mule, if u have ton of shrs
— Raj R (@rajramaswamy) February 16, 2016
$PETX filed a marketing application in the EU for the osteoarthritis drug Galliprant. A next thing to watch for is if they land a partner.
— Brad Loncar (@bradloncar) February 17, 2016
$TRIL..$7.75 on watch here as some tutes put the "thrill" in the "TRIL" in the AH. On my watch list again. Solid buying hard to ignore.
— Sheff (@SheffStation) February 16, 2016
Today's #Biotech Winners$PSTI +30.9%$RMTI +21.3%$CYTX +20.3% $ONCE +19.3%$PGNX +18.2%$NWBO +17.2%$TGTX +13.3%$BLUE +11.9%$EYES +12%
— Biotech 5 (@Biotech_5) February 16, 2016
seems like forever ago the $XBI saw this $50 level...but it was only ~2wks
— zach (@zbiotech) February 17, 2016
$EDIT competitor --> USPTO has granted a #CRISPR patent to Doudna's Caribou Bioscienceshttps://t.co/Ex1ua9gQEi
— Andy Biotech (@AndyBiotech) February 17, 2016
#Biotech Data Remaining in Q1$AMGN Romo -> $RDUS$ALDR Ph2b$ALDX Ph2$CLDX Ph3 Interim$CPXX OS$GWPH Ph3$MRNS Ph2$PTLA Ph3$VCEL Ph2b
— Andy Biotech (@AndyBiotech) February 17, 2016
$tril will have abstracts at aacr2016 as event just added on website. Crossing fingers on combo data
— Joshua B (@srqstockpicker) February 17, 2016
Baker Bros 13F. Top Holding: $INCY $SGEN $ABBV $ACAD $GHDX $ANAC $BMRN
— Bio Stocks™ (@BioStocks) February 18, 2016
Orbimed top % stake: $DMTX 21.5% $PIRS 18.25% $ROKA 17.8% $RLYP 17.75% $AFMD 15.4% $LOXO 11.3%
— Bio Stocks™ (@BioStocks) February 18, 2016
maybe that's why the Fed is so against being audited, they're embarrassed to be holding a bunch of crappy biotech stocks
— StockCats (@StockCats) February 18, 2016
Drugs to Halt, or Reverse, Deadly Lung Scarring? Third Rock Bets $45M it Can Be Done. New @forbeshealth https://t.co/aLjZMd9WUW
— Luke Timmerman (@ldtimmerman) February 18, 2016
Couple is giving $7.2 million toward efforts to lower drug prices https://t.co/SBzKCILb6D
— Brad Loncar (@bradloncar) February 18, 2016
Nice move on $TTNP to over $4.20 from $3.50 (20%) few days ago. PDUFA closing in over next week. Profit is key in this market.
— Sheff (@SheffStation) February 18, 2016
$XBI $IBB $SBIO all triggered short term upside moves. Still cautious, as they are under the 50 but it still is encouraging price action.
— BioBounce.com (@BioBounce) February 18, 2016
Google unit stakes biotech claim with lease of entire Onyx campus: Google's… https://t.co/F71OOJBqb5 BiotechSF blog
— Ron Leuty (@rleuty_biotech) February 18, 2016
#Biotwitter feels good to make money again!!! To bad the 2016 ditch is so dam big!
— BioHunter (@TheBio_Hunter) February 18, 2016
Canadian provinces close the door on coverage of an Alexion rare disease drug over its price.. https://t.co/GdpzpsGcQf #pharma $ALXN
— pharmalot (@pharmalot) February 18, 2016
Got to say, that pop let me exit some losing trades and now I can go back to short term trading. Much happier now.
— Michael Torres, PhD (@Mykalt45) February 18, 2016
@rajramaswamy Hear ya I have absolutely no interest in $AERI at all.
— dough (@tgtxdough) February 18, 2016
$XBI & $IBB ugly "Dark Cloud Cover" candlestick today.. just what I expected today morning with "Three Gaps Up" !! pic.twitter.com/fzAYjI9rzU
— Joe (@GantosJ) February 18, 2016
.@oru2day @JPZaragoza1 I wish them all the best but wouldn't bet the farm on Phase 2 AML data. Phase 3 can be a big tall wall of hurt.....
— Paul D. Rennert (@PDRennert) February 18, 2016
BB BIOTECH AG: Outlook for the biotech sector remains positive despite sell-off | Benzinga https://t.co/MkI1RYQxK3
— Audi (@odibro) February 19, 2016
if u gotta make so many assumptions given lack of disclosure/information to decipher health of biz, maybe the co doesn't want u to know $VRX
— zach (@zbiotech) February 19, 2016
CITI- upgrading SMID health care sector to equal weight from under weight. $ibb $xbi
— BATTLE THE BTK (@BioWino) February 19, 2016
@JacobPlieth @MaxJacobsEdison $ATHX conducted a robust, well-designed clinical trial. The results were negative. Unequivocal. It’s over.
— Adam Feuerstein (@adamfeuerstein) February 19, 2016
All out of $CPXX from $1.25. Been a long time since I've had a Bio trade turn out that well... #remembertheGNOM
— Davey (@hayitsDavey) February 19, 2016
Seems day trading labu is the best way to play biotechs. Big daily moves and no risk holding overnight.
— Festo (@Festo50) February 19, 2016
What's killing people over 65? Fascinating comparison with 15 years ago. @qz chart pic.twitter.com/W0HKYWN5Qe
— Paul Kirby (@paul1kirby) February 10, 2016
